These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 27872078)

  • 1. Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.
    Diep JK; Jacobs DM; Sharma R; Covelli J; Bowers DR; Russo TA; Rao GG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae.
    Diep JK; Sharma R; Ellis-Grosse EJ; Abboud CS; Rao GG
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203494
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Huang D; Yu B; Diep JK; Sharma R; Dudley M; Monteiro J; Kaye KS; Pogue JM; Abboud CS; Rao GG
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.
    Bulman ZP; Satlin MJ; Chen L; Kreiswirth BN; Shin BS; Walsh TJ; Holden PN; Forrest A; Nation RL; Li J; Tsuji BT
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae.
    Aye SM; Galani I; Yu H; Wang J; Chen K; Wickremasinghe H; Karaiskos I; Bergen PJ; Zhao J; Velkov T; Giamarellou H; Lin YW; Tsuji BT; Li J
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32393492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae.
    Pankey GA; Ashcraft DS
    Diagn Microbiol Infect Dis; 2011 Aug; 70(4):561-4. PubMed ID: 21767715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes.
    Sharma R; Patel S; Abboud C; Diep J; Ly NS; Pogue JM; Kaye KS; Li J; Rao GG
    Int J Antimicrob Agents; 2017 Feb; 49(2):224-232. PubMed ID: 28040408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae.
    Lin YW; Abdul Rahim N; Zhao J; Han ML; Yu HH; Wickremasinghe H; Chen K; Wang J; Paterson DL; Zhu Y; Rao GG; Zhou QT; Forrest A; Velkov T; Li J
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.
    Bulman ZP; Zhao M; Satlin MJ; Chen L; Kreiswirth BN; Walsh TJ; Nation RL; Li J; Tsuji BT
    Int J Antimicrob Agents; 2018 Jul; 52(1):114-118. PubMed ID: 29486233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.
    Lim TP; Cai Y; Hong Y; Chan EC; Suranthran S; Teo JQ; Lee WH; Tan TY; Hsu LY; Koh TH; Tan TT; Kwa AL
    Antimicrob Agents Chemother; 2015 May; 59(5):2515-24. PubMed ID: 25691628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.
    Wiskirchen DE; Koomanachai P; Nicasio AM; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1420-7. PubMed ID: 21282442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments.
    Lagerbäck P; Khine WW; Giske CG; Tängdén T
    J Antimicrob Chemother; 2016 Aug; 71(8):2321-5. PubMed ID: 27334665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials.
    Barth N; Ribeiro VB; Zavascki AP
    Antimicrob Agents Chemother; 2015; 59(6):3596-7. PubMed ID: 25801560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.
    Albiero J; Sy SK; Mazucheli J; Caparroz-Assef SM; Costa BB; Alves JL; Gales AC; Tognim MC
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4128-39. PubMed ID: 27139468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
    Tängdén T; Hickman RA; Forsberg P; Lagerbäck P; Giske CG; Cars O
    Antimicrob Agents Chemother; 2014; 58(3):1757-62. PubMed ID: 24395223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents.
    Bratu S; Tolaney P; Karumudi U; Quale J; Mooty M; Nichani S; Landman D
    J Antimicrob Chemother; 2005 Jul; 56(1):128-32. PubMed ID: 15917285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In pursuit of the triple crown: mechanism-based pharmacodynamic modelling for the optimization of three-drug combinations against KPC-producing Klebsiella pneumoniae.
    Onufrak NJ; Smith NM; Satlin MJ; Bulitta JB; Tan X; Holden PN; Nation RL; Li J; Forrest A; Tsuji BT; Bulman ZP
    Clin Microbiol Infect; 2020 Sep; 26(9):1256.e1-1256.e8. PubMed ID: 32387437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae.
    Tascini C; Tagliaferri E; Giani T; Leonildi A; Flammini S; Casini B; Lewis R; Ferranti S; Rossolini GM; Menichetti F
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3990-3. PubMed ID: 23752510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Bulik CC; Christensen H; Li P; Sutherland CA; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2010 Feb; 54(2):804-10. PubMed ID: 19995927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.